Synairgen (SNG)

 

Latest News

Holding(s) in Company

RNS Number: 4682M Synairgen plc 13 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Synairgen updates on AZD9412

Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim ...

FTSE up on airlines, house builders after sluggish start

London stocks shrugged offer an early sour start to be cautiously ahead, with both the blue-chip and mid-cap indices risin...

AZD9412 Clinical Trial Update

RNS Number: 2831M Synairgen plc 12 October 2016 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Clinical Trial Update ~ AstraZeneca to focus on key secondary endpoints with results expected in Q1 2017 ~ Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today t...

All News

DateHeadlineSource
13-10-16Holding(s) in CompanyRNS
12-10-16Synairgen updates on AZD9412StockMarketWire
12-10-16FTSE up on airlines, house builders after sluggish startStockMarketWire
12-10-16AZD9412 Clinical Trial UpdateRNS
22-09-16Broker Forecast - N+1 Singer issues a broker note on Synairgen PLCStockMarketWire
22-09-16Synairgen widens H1 pretax lossStockMarketWire
22-09-16Interim results for six months ended 30 June 2016RNS
08-09-16Notice of Interim ResultsRNS
14-06-16Result of AGMRNS
07-06-16Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?Motley Fool
17-05-16Posting of Annual Report and Notice of AGMRNS
21-04-16Holding(s) in CompanyRNS
23-03-16Synairgen options exercised StockMarketWire
23-03-16Exercise of OptionsRNS
22-03-16Broker Forecast - finnCap issues a broker note on Synairgen PLCStockMarketWire
22-03-16Preliminary results for the year ended 31 Dec 2015RNS
22-03-16Positive LOXL2 resultsRNS
03-03-16Notice of Preliminary ResultsRNS
16-11-15Adoption of FRS 101 - Reduced Disclosure FrameworkRNS
13-11-15Holding(s) in CompanyRNS
13-11-15Holding(s) in CompanyRNS
13-11-15Holding(s) in CompanyRNS
12-11-15Director Deals - Synairgen PLC (SNG)StockMarketWire
12-11-15Director Deals - Synairgen PLC (SNG)StockMarketWire
12-11-15Director Deals - Synairgen PLC (SNG)StockMarketWire
12-11-15Director Deals - Synairgen PLC (SNG)StockMarketWire
12-11-15Directors' Share PurchaseRNS
28-10-15Grant of optionsRNS
16-09-15Synairgen swings to H1 pretax lossStockMarketWire
16-09-15Interim ResultsRNS
21-08-15Synairgen schedules interimsStockMarketWire
21-08-15Notice of Interim ResultsRNS
05-08-15Synairgen announces research collaborationStockMarketWire
05-08-15Synairgen announces research collaborationStockMarketWire
05-08-15Synairgen announces research collaborationRNS
22-07-15SNG says AstraZeneca beings Phase II Trial of AZD9412StockMarketWire
22-07-15AstraZeneca commences Phase II TrialRNS
22-06-15Synairgen resolutions passed at AGMStockMarketWire
22-06-15Result of AGMRNS
02-06-15Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:SNG Editorial
  • Regulatory news feed for LSE:SNG Regulatory